ReviewFrontiers in immunology2022
Early-Life Lung and Gut Microbiota Development and Respiratory Syncytial Virus Infection.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- The impact for causal associations between common diseases and inflammatory bowel disease: a disease-wide bidirectional Mendelian randomization study.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Early-life respiratory syncytial virus infection and asthma.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Antibiotic-induced Malassezia expansion in the infant gut promotes early-life immune dysregulation and airway inflammation in mice.Nature communications · 2026Article
- Lung Microbiome Diversity, Infection Dynamics, and Microbe-Mediated Cross-Protection.MicrobiologyOpen · 2026Review
- Predictive Model for Critical Illness Infection in Hospitalized Children with RSV Infection: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- The gut-lung axis in ARDS: beyond microbial translocation.Respiratory research · 2026Review
- Multiple co-infections and risk of severe outcomes in children with respiratory syncytial virus infection.BMC infectious diseases · 2026Article
- Respiratory Viral Co-Infections in Pediatric Patients: Clinical Impact and Implications for Healthcare Practice-A Narrative Review.Healthcare (Basel, Switzerland) · 2026Review
- Hidden connection: Impact of the gut microbiota on respiratory diseases in children (Review).Molecular medicine reports · 2026Review
- Resveratrol as an Adjunct Antiviral Agent in Pediatric Viral Infections: A Review on Mechanistic Insights and Gut Microbiota Modulation.International journal of molecular sciences · 2025Review
- Exploring the Probiotic Potential of Bacteroides spp. Within One Health Paradigm.Probiotics and antimicrobial proteins · 2025Review
- Deciphering respiratory viral infections by harnessing organ-on-chip technology to explore the gut-lung axis.Open biology · 2025Review
- Short-Chain Fatty Acids: Promising Therapeutic Targets for Respiratory Syncytial Virus Infection.Clinical reviews in allergy & immunology · 2025Review
- The potential immunomodulatory role of human milk oligosaccharides in prevention of viral infections and development of asthma in early life.Frontiers in immunology · 2025Review
- Association between gut microbiota and acute upper respiratory tract infection: a Mendelian randomization study.Scientific reports · 2024Article
- Microbiome modifications by steroids during viral exacerbation of asthma and in healthy mice.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Causal effect of gut microbiota on occurrence of herpes zoster and postherpetic neuralgia, and role of Tyzzerella 3.European journal of medical research · 2024Article
- Application of Microbiome-Based Therapies in Chronic Respiratory Diseases.Journal of microbiology (Seoul, Korea) · 2024Review
- The antibiotic resistance reservoir of the lung microbiome expands with age in a population of critically ill patients.Nature communications · 2024Observational
- Factors associated with severe respiratory syncytial virus infection among hospitalized children in Thammasat University Hospital.F1000Research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Several environmental factors can influence the development and establishment of the early-life microbiota. For example, exposure to different environmental factors from birth to childhood will shape the lung and gut microbiota and the development of the immune system, which will impact respiratory tract infection and widespread disease occurrence during infancy and later in life. Respiratory syncytial virus (RSV) infects most infants by the age of two and is the primary cause of bronchiolitis in children worldwide. Approximately a third of infants hospitalized with bronchiolitis develop asthma later in life. However, it is unclear what factors increase susceptibility to severe RSV-bronchiolitis and the subsequent asthma development. In recent years, the role of the gut and lung microbiota in airway diseases has received increased interest, and more studies have focused on this field. Different epidemiological studies and experimental animal models have associated early-life gut microbiota dysbiosis with an increased risk of lung disease later in life. This work will review published evidence that correlated environmental factors that affect the early-life microbiota composition and their role in developing severe RSV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.